Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus PRRT dose-escalation study in advanced gastroenteropancreatic neuroendocrine tumors
NL-OMON21221Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib and lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Erasmus MC. Primary endpoint: Maximum tolerated dose. Started Jan 2022; status: recruiting.
02
Drugs
olapariblutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON21221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21221.